Your vote at this year’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for December 17, 2024, is ...

Recurrent Ovarian Cancer Reported positive top-line, protocol-planned interim report data from the study of Ampligen combined with pembrolizumab ... of 9,042 clinical vials of Ampligen; Announced ...

The company said it plans to launch Winrevair by the end of next month and has set a list price of $14,000 per vial. The drug is administered as a subcutaneous injection every three weeks ...

Get detailed information on Pembrolizumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

CHICAGO — In patients with stage IVB anaplastic thyroid cancer, the inclusion of adjuvant pembrolizumab to conventional multimodal therapy shows significant benefits in reducing the recurrence ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings that ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Dr. Shannon Westin (Host), Dr. Brian Slomovitz (Guest) Dr. Shannon Westin and her guest, Dr. Brian Slomovitz discuss the article “Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer. Ivonescimab reduced the risk of ...

As of 3:37 PM EST. Market Open. CULVER CITY, Calif., October 24, 2024--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an ...